Minimally invasive lobectomy with neoadjuvant targeted therapy: the Zhejiang Cancer Hospital experience
Non-small cell lung carcinoma (NSCLC) is a growing threat worldwide. The management of NSCLC is suggested to be systematic, which means the collaboration of multiple departments. For some NSCLC patients, neoadjuvant treatment is necessary for better prognosis. The role of neoadjuvant chemotherapy is well accepted. Targeted therapy is prior than chemotherapy for stage IV NSCLC patients, whether it shows an advantage in neoadjuvant management is unknown. Our team at Zhejiang Cancer Hospital reported a case treated with neoadjuvant targeted therapy, followed with radical resection, and try to provide some information to standardize the management of NSCLC.